Long-term of Remote Ischemic Preconditioning and Mindfulness in Patients With Mild Hypertension
Recruiting · NCT04753840 · Interventional (participants receive a specific treatment) · Lead sponsor: Henan Institute of Cardiovascular Epidemiology
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
According to the latest survey data of China hypertension annual meeting, there are about 300 million patients with hypertension in China, with 10 million new cases of hypertension each year, and there is an obvious trend of younger people. In particular, young and middle-aged people are in a state of mild hypertension for a long time, which causes great pressure on health and medical treatment. At present, the main clinical measures for mild hypertension are to change their eating habits, quit smoking and alcohol, exercise and other lifestyle changes, as well as drug control. For most patients with mild hypertension, drug control is not the best choice. It has been reported that remote ischemic preconditioning (RIPC) may play an effective role in reducing blood pressure .The purpose of this study was to investigate the extent of long-term application of RIPC to reduce blood pressure in patients with mild hypertension.
Who can take part
Inclusion criteria
- Diagnosed patients with mild hypertension (SBP: 140\~159mmHg; DBP: 90\~99mmHg)
Exclusion criteria
- Cannot tolerate RIPC
- Non-essential hypertension
- patients who have uncontrolled severe arrhythmia, diabetes, electrolyte disturbance
- patients who have severe organic diseases such acute myocardial infarction, cardiac insufficiency, abnormal renal function, etc.
Where it is running
1 location listed.
- Fuwai central China Cardiovascular hospital - Zhengzhou, Henan, China